nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Telmisartan—PPARG—melanoma	0.013	0.493	CrCbGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—melanoma	0.00577	0.00665	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FASLG—melanoma	0.00565	0.00651	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FGF2—melanoma	0.00548	0.00631	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FAS—melanoma	0.00545	0.00628	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR1—melanoma	0.00544	0.00627	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCR2—melanoma	0.00544	0.00627	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2RL1—melanoma	0.0054	0.00622	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—MC1R—melanoma	0.00536	0.00617	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-A—melanoma	0.00536	0.00617	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCR7—melanoma	0.00514	0.00592	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DRB1—melanoma	0.00489	0.00564	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL1—melanoma	0.00483	0.00557	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—KISS1—melanoma	0.00481	0.00555	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—F2R—melanoma	0.00468	0.0054	CbGpPWpGaD
Azilsartan medoxomil—Telmisartan—ABCB1—melanoma	0.00467	0.177	CrCbGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR1—melanoma	0.00466	0.00537	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—melanoma	0.00466	0.00537	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CTNNB1—melanoma	0.00465	0.00535	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—F2R—melanoma	0.00462	0.00533	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—MC1R—melanoma	0.00459	0.00529	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDNRB—melanoma	0.00453	0.00523	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CD80—melanoma	0.00452	0.00521	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDNRB—melanoma	0.00448	0.00516	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR7—melanoma	0.0044	0.00507	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Vemurafenib—melanoma	0.00436	0.0411	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Vemurafenib—melanoma	0.00435	0.041	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—melanoma	0.00432	0.00498	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—melanoma	0.00429	0.00494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNA11—melanoma	0.00428	0.00494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—melanoma	0.00426	0.00491	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP8—melanoma	0.0042	0.00485	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—melanoma	0.00419	0.00483	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—F2RL1—melanoma	0.00411	0.00474	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—melanoma	0.00405	0.00467	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Vemurafenib—melanoma	0.00402	0.0379	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNAQ—melanoma	0.00398	0.00459	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCR4—melanoma	0.00397	0.00458	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRM3—melanoma	0.00386	0.00445	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.00383	0.00441	CbGpPWpGaD
Azilsartan medoxomil—Candesartan—ABCB1—melanoma	0.00376	0.143	CrCbGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—melanoma	0.00368	0.00424	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—KISS1—melanoma	0.00366	0.00422	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00365	0.0042	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—F2R—melanoma	0.00362	0.00417	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—TAS2R60—melanoma	0.0036	0.00416	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IFNG—melanoma	0.00357	0.00412	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.00356	0.0041	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR1—melanoma	0.00355	0.00409	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—EDNRB—melanoma	0.0035	0.00404	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—melanoma	0.0035	0.00404	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—MC1R—melanoma	0.0035	0.00403	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRM1—melanoma	0.00335	0.00386	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCR7—melanoma	0.00335	0.00386	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—melanoma	0.00334	0.00384	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—melanoma	0.00332	0.00383	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TAS2R60—melanoma	0.00327	0.00377	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00326	0.0307	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—melanoma	0.00318	0.00367	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—melanoma	0.00318	0.00366	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—melanoma	0.00311	0.00359	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.0031	0.00357	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—EDN1—melanoma	0.00309	0.00356	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Vemurafenib—melanoma	0.00309	0.0291	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Vemurafenib—melanoma	0.00306	0.0288	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—EDN1—melanoma	0.00305	0.00351	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—melanoma	0.00304	0.0035	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.003	0.00346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR2—melanoma	0.00278	0.0032	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.00276	0.00318	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL1—melanoma	0.00273	0.00315	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PLCB4—melanoma	0.00273	0.00315	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Vemurafenib—melanoma	0.00272	0.0256	CcSEcCtD
Azilsartan medoxomil—Fatigue—Vemurafenib—melanoma	0.00271	0.0256	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—melanoma	0.0027	0.00311	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—WNT5A—melanoma	0.00269	0.0031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00267	0.00307	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.00259	0.00298	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ALB—melanoma	0.00254	0.0962	CrCbGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.00253	0.00291	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—melanoma	0.00248	0.00286	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PLCB4—melanoma	0.00248	0.00286	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL1—melanoma	0.00248	0.00286	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ABCB1—melanoma	0.00242	0.0918	CrCbGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—F2R—melanoma	0.00236	0.00272	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—F2RL1—melanoma	0.00232	0.00268	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—melanoma	0.00231	0.00267	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Carmustine—melanoma	0.00231	0.0218	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Carmustine—melanoma	0.0023	0.0217	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDNRB—melanoma	0.00229	0.00264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DRAP1—melanoma	0.00227	0.00262	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYO7A—melanoma	0.00227	0.00262	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Vemurafenib—melanoma	0.00226	0.0213	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Temozolomide—melanoma	0.00223	0.021	CcSEcCtD
Azilsartan medoxomil—Pruritus—Vemurafenib—melanoma	0.00223	0.021	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Temozolomide—melanoma	0.00222	0.021	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRM3—melanoma	0.00218	0.00252	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Vemurafenib—melanoma	0.00215	0.0203	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—F2RL1—melanoma	0.00211	0.00243	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Vemurafenib—melanoma	0.00208	0.0196	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—KISS1—melanoma	0.00207	0.00239	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Temozolomide—melanoma	0.00205	0.0194	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.00204	0.00236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCR4—melanoma	0.00203	0.00234	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR1—melanoma	0.00201	0.00231	CbGpPWpGaD
Azilsartan medoxomil—Rash—Vemurafenib—melanoma	0.00198	0.0187	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRM3—melanoma	0.00198	0.00229	CbGpPWpGaD
Azilsartan medoxomil—Dermatitis—Vemurafenib—melanoma	0.00198	0.0187	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MC1R—melanoma	0.00198	0.00228	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TAS2R60—melanoma	0.00193	0.00223	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRM1—melanoma	0.00189	0.00218	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCR7—melanoma	0.00189	0.00218	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KISS1—melanoma	0.00188	0.00217	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Vemurafenib—melanoma	0.00187	0.0176	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR1—melanoma	0.00182	0.0021	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Temozolomide—melanoma	0.0018	0.017	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MC1R—melanoma	0.00179	0.00207	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.00179	0.00207	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RHOB—melanoma	0.00172	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRM1—melanoma	0.00172	0.00198	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCR7—melanoma	0.00172	0.00198	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00167	0.0157	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—melanoma	0.00165	0.0019	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Temozolomide—melanoma	0.00158	0.0149	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR2—melanoma	0.00157	0.00181	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RHOB—melanoma	0.00156	0.0018	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Temozolomide—melanoma	0.00156	0.0147	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—EDN1—melanoma	0.00156	0.00179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RAC2—melanoma	0.00154	0.00178	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Dactinomycin—melanoma	0.00153	0.0145	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—melanoma	0.00148	0.014	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—melanoma	0.00148	0.0139	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL1—melanoma	0.00147	0.00169	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLCB4—melanoma	0.00147	0.00169	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Carmustine—melanoma	0.00144	0.0135	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR2—melanoma	0.00142	0.00164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RAC2—melanoma	0.0014	0.00162	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Temozolomide—melanoma	0.00139	0.0131	CcSEcCtD
Azilsartan medoxomil—Fatigue—Temozolomide—melanoma	0.00139	0.0131	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—WNT5A—melanoma	0.00138	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CUL3—melanoma	0.00138	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TRRAP—melanoma	0.00138	0.00159	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Bleomycin—melanoma	0.00137	0.0129	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—melanoma	0.00137	0.0129	CcSEcCtD
Azilsartan medoxomil—Pruritus—Bleomycin—melanoma	0.00135	0.0127	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKR1B10—melanoma	0.00134	0.00155	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—F2R—melanoma	0.00133	0.00154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDNRB—melanoma	0.00129	0.00149	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Dactinomycin—melanoma	0.00128	0.012	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Docetaxel—melanoma	0.00126	0.0119	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—F2RL1—melanoma	0.00125	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GAB2—melanoma	0.00122	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNA11—melanoma	0.00122	0.00141	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Dactinomycin—melanoma	0.00122	0.0115	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—F2R—melanoma	0.00121	0.0014	CbGpPWpGaD
Azilsartan medoxomil—Rash—Bleomycin—melanoma	0.0012	0.0113	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Bleomycin—melanoma	0.0012	0.0113	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.0012	0.00138	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Carmustine—melanoma	0.00119	0.0113	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDNRB—melanoma	0.00117	0.00135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRM3—melanoma	0.00117	0.00135	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Temozolomide—melanoma	0.00115	0.0109	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCR4—melanoma	0.00115	0.00132	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.00115	0.00132	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Carmustine—melanoma	0.00114	0.0107	CcSEcCtD
Azilsartan medoxomil—Pruritus—Temozolomide—melanoma	0.00114	0.0107	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNAQ—melanoma	0.00113	0.00131	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Bleomycin—melanoma	0.00113	0.0107	CcSEcCtD
Azilsartan medoxomil—Rash—Dactinomycin—melanoma	0.00112	0.0106	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KISS1—melanoma	0.00111	0.00128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GAB2—melanoma	0.00111	0.00128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNA11—melanoma	0.00111	0.00128	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00111	0.0104	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.0011	0.00127	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Carmustine—melanoma	0.0011	0.0104	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Temozolomide—melanoma	0.0011	0.0104	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.00109	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.00109	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SKI—melanoma	0.00108	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR1—melanoma	0.00108	0.00124	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Temozolomide—melanoma	0.00106	0.01	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MC1R—melanoma	0.00106	0.00122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—melanoma	0.00106	0.00122	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Dactinomycin—melanoma	0.00106	0.00996	CcSEcCtD
Azilsartan medoxomil—Rash—Carmustine—melanoma	0.00105	0.00989	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—melanoma	0.00105	0.00989	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Carmustine—melanoma	0.00105	0.00989	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT3—melanoma	0.00105	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCR4—melanoma	0.00104	0.0012	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Docetaxel—melanoma	0.00104	0.0098	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNAQ—melanoma	0.00103	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.00103	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCR7—melanoma	0.00102	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRM1—melanoma	0.00102	0.00117	CbGpPWpGaD
Azilsartan medoxomil—Rash—Temozolomide—melanoma	0.00101	0.00956	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Temozolomide—melanoma	0.00101	0.00955	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SUFU—melanoma	0.00099	0.00114	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Carmustine—melanoma	0.000989	0.00932	CcSEcCtD
Azilsartan medoxomil—Nausea—Temozolomide—melanoma	0.000955	0.00901	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT3—melanoma	0.000951	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000946	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RHOB—melanoma	0.000924	0.00107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BCL2L11—melanoma	0.000924	0.00107	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—melanoma	0.000923	0.00871	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—melanoma	0.000922	0.0087	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC6—melanoma	0.000888	0.00102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—EDN1—melanoma	0.00088	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.000876	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CSF2—melanoma	0.00086	0.000991	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR2—melanoma	0.000842	0.00097	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—melanoma	0.000841	0.00097	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000838	0.000966	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAC2—melanoma	0.000828	0.000955	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCA—melanoma	0.000824	0.00095	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFC—melanoma	0.000815	0.00094	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WNT5A—melanoma	0.000815	0.00094	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EDN1—melanoma	0.000799	0.000921	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CSF2—melanoma	0.000781	0.0009	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Docetaxel—melanoma	0.000767	0.00724	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RAC1—melanoma	0.000764	0.000881	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Docetaxel—melanoma	0.000757	0.00714	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCA—melanoma	0.000749	0.000863	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Docetaxel—melanoma	0.000732	0.0069	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAP2K2—melanoma	0.000732	0.000843	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—F2R—melanoma	0.000716	0.000825	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Docetaxel—melanoma	0.000707	0.00667	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RAC1—melanoma	0.000694	0.0008	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDNRB—melanoma	0.000693	0.000799	CbGpPWpGaD
Azilsartan medoxomil—Rash—Docetaxel—melanoma	0.000674	0.00636	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—melanoma	0.000674	0.00635	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTK2B—melanoma	0.000673	0.000776	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNA11—melanoma	0.000655	0.000755	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GAB2—melanoma	0.000655	0.000755	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FLT1—melanoma	0.000652	0.000751	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—melanoma	0.000646	0.000744	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Docetaxel—melanoma	0.000635	0.00599	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCR4—melanoma	0.000615	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FOXO4—melanoma	0.000615	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HDAC2—melanoma	0.000615	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNAQ—melanoma	0.000609	0.000701	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—melanoma	0.000586	0.000676	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SYK—melanoma	0.000572	0.00066	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—melanoma	0.000568	0.000654	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NGFR—melanoma	0.000562	0.000647	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ITGAV—melanoma	0.000562	0.000647	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT3—melanoma	0.000562	0.000647	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SOCS1—melanoma	0.00052	0.000599	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAP2K1—melanoma	0.000519	0.000598	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—S100B—melanoma	0.000519	0.000598	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—melanoma	0.000515	0.000594	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB4—melanoma	0.000496	0.000572	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—melanoma	0.000495	0.00057	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN2B—melanoma	0.000492	0.000567	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD86—melanoma	0.000476	0.000548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—melanoma	0.000475	0.000548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EDN1—melanoma	0.000472	0.000544	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF1—melanoma	0.000461	0.000532	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CSF2—melanoma	0.000461	0.000532	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—melanoma	0.000454	0.000524	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—E2F1—melanoma	0.000451	0.00052	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—melanoma	0.000449	0.000518	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFRA—melanoma	0.000447	0.000515	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCA—melanoma	0.000442	0.00051	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ITGB3—melanoma	0.000442	0.00051	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPP1—melanoma	0.000434	0.0005	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP2K2—melanoma	0.000432	0.000498	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—melanoma	0.000432	0.000498	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—melanoma	0.000413	0.000476	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—melanoma	0.000411	0.000474	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAC1—melanoma	0.00041	0.000473	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—melanoma	0.000393	0.000453	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KDR—melanoma	0.000376	0.000433	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FN1—melanoma	0.000362	0.000417	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH1—melanoma	0.000354	0.000408	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CD80—melanoma	0.000347	0.0004	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—melanoma	0.000346	0.000399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KIT—melanoma	0.000346	0.000399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APC—melanoma	0.000346	0.000399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—NRAS—melanoma	0.000346	0.000399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGF—melanoma	0.000342	0.000395	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—melanoma	0.000332	0.000382	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BRAF—melanoma	0.000326	0.000375	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—melanoma	0.000317	0.000366	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK1—melanoma	0.000316	0.000364	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—melanoma	0.000316	0.000364	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP2K1—melanoma	0.000306	0.000353	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—melanoma	0.000304	0.000351	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—melanoma	0.000302	0.000348	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—melanoma	0.000298	0.000344	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF2—melanoma	0.000292	0.000336	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—melanoma	0.000274	0.000316	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MDM2—melanoma	0.000273	0.000314	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB2—melanoma	0.000269	0.00031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—melanoma	0.000265	0.000306	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—melanoma	0.000255	0.000294	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—melanoma	0.000253	0.000292	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1B—melanoma	0.000249	0.000287	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—melanoma	0.000246	0.000284	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—melanoma	0.000244	0.000281	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—melanoma	0.000244	0.000281	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—melanoma	0.000243	0.00028	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—melanoma	0.000238	0.000274	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTNNB1—melanoma	0.000235	0.000271	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—melanoma	0.000231	0.000266	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—melanoma	0.00023	0.000265	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—melanoma	0.000229	0.000264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKB1—melanoma	0.000228	0.000263	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—melanoma	0.000224	0.000258	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—melanoma	0.000207	0.000239	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—melanoma	0.000205	0.000236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRAS—melanoma	0.000205	0.000236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—melanoma	0.000196	0.000226	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—melanoma	0.000191	0.00022	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK1—melanoma	0.000186	0.000215	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—melanoma	0.000186	0.000215	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—melanoma	0.000176	0.000203	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—melanoma	0.000162	0.000186	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—melanoma	0.000157	0.00018	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—melanoma	0.00015	0.000173	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—melanoma	0.000143	0.000165	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—melanoma	0.000132	0.000152	CbGpPWpGaD
